

David J Gordon

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8057441/publications.pdf>

Version: 2024-02-01

32
papers

2,505
citations

430874

18
h-index

434195

31
g-index

32
all docs

32
docs citations

32
times ranked

3963
citing authors

#	ARTICLE	IF	CITATIONS
1	Oncogenic RABL6A promotes NF1-associated MPNST progression in vivo. <i>Neuro-Oncology Advances</i> , 2022, 4, vdac047.	0.7	3
2	Disruption of dNTP homeostasis by ribonucleotide reductase hyperactivation overcomes AML differentiation blockade. <i>Blood</i> , 2022, 139, 3752-3770.	1.4	12
3	Inhibitor of DNA binding 2 (ID2) regulates the expression of developmental genes and tumorigenesis in ewing sarcoma. <i>Oncogene</i> , 2022, 41, 2873-2884.	5.9	2
4	The translational repressor 4E-BP1 regulates RRM2 levels and functions as a tumor suppressor in Ewing sarcoma tumors. <i>Oncogene</i> , 2021, 40, 564-577.	5.9	13
5	Combination therapies for MPNSTs targeting RABL6A-RB1 signaling. <i>Oncotarget</i> , 2021, 12, 10-14.	1.8	5
6	Preclinical efficacy of prexasertib in acute lymphoblastic leukemia. <i>British Journal of Haematology</i> , 2021, 194, 1094-1098.	2.5	1
7	Inhibition of the ATR-CHK1 Pathway in Ewing Sarcoma Cells Causes DNA Damage and Apoptosis via the CDK2-Mediated Degradation of RRM2. <i>Molecular Cancer Research</i> , 2020, 18, 91-104.	3.4	43
8	Eltrombopag inhibits the proliferation of Ewing sarcoma cells via iron chelation and impaired DNA replication. <i>BMC Cancer</i> , 2020, 20, 1171.	2.6	7
9	CDKs in Sarcoma: Mediators of Disease and Emerging Therapeutic Targets. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3018.	4.1	30
10	Pharmacologic Ascorbate Primes Pancreatic Cancer Cells for Death by Rewiring Cellular Energetics and Inducing DNA Damage. <i>Molecular Cancer Research</i> , 2019, 17, 2102-2114.	3.4	21
11	SN-38 Conjugated Gold Nanoparticles Activated by Ewing Sarcoma Specific mRNAs Exhibit <i>In Vitro</i> and <i>In Vivo</i> Efficacy. <i>Bioconjugate Chemistry</i> , 2018, 29, 1111-1118.	3.6	16
12	mTORC1/2 and Protein Translation Regulate Levels of CHK1 and the Sensitivity to CHK1 Inhibitors in Ewing Sarcoma Cells. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 2676-2688.	4.1	27
13	Development of Secondary Acute Myeloid Leukemia in a Pediatric Patient Concurrently Receiving Primary Therapy for Ewing Sarcoma. <i>Journal of Pediatric Hematology/Oncology</i> , 2017, 39, e370-e372.	0.6	4
14	Inhibition of CHK1 sensitizes Ewing sarcoma cells to the ribonucleotide reductase inhibitor gemcitabine. <i>Oncotarget</i> , 2017, 8, 87016-87032.	1.8	23
15	Modeling the initiation of Ewing sarcoma tumorigenesis in differentiating human embryonic stem cells. <i>Oncogene</i> , 2016, 35, 3092-3102.	5.9	20
16	Gene expression signature based screening identifies ribonucleotide reductase as a candidate therapeutic target in Ewing sarcoma. <i>Oncotarget</i> , 2016, 7, 63003-63019.	1.8	31
17	Drug conjugated nanoparticles activated by cancer cell specific mRNA. <i>Oncotarget</i> , 2016, 7, 38243-38256.	1.8	17
18	Aurea Mediocritas: The Importance of a Balanced Genome. <i>Cold Spring Harbor Perspectives in Biology</i> , 2014, 6, a015842-a015842.	5.5	19

#	ARTICLE	IF	CITATIONS
19	Causes and consequences of aneuploidy in cancer. <i>Nature Reviews Genetics</i> , 2012, 13, 189-203.	16.3	700
20	A pediatric case series of acute hemolysis after administration of intravenous immunoglobulin. <i>American Journal of Hematology</i> , 2009, 84, 771-772.	4.1	24
21	Peptide-Based Inhibitors of Amyloid Assembly. <i>Methods in Enzymology</i> , 2006, 413, 273-312.	1.0	126
22	Spatial Separation of β -Sheet Domains of β -Amyloid: Disruption of Each β -Sheet by N-Methyl Amino Acids. <i>Biochemistry</i> , 2006, 45, 9485-9495.	2.5	42
23	A β 40-Lactam(D23/K28) Models a Conformation Highly Favorable for Nucleation of Amyloid. <i>Biochemistry</i> , 2005, 44, 6003-6014.	2.5	241
24	Increasing the Amphiphilicity of an Amyloidogenic Peptide Changes the β -Sheet Structure in the Fibrils from Antiparallel to Parallel. <i>Biophysical Journal</i> , 2004, 86, 428-434.	0.5	119
25	Probing the Role of Backbone Hydrogen Bonding in β -Amyloid Fibrils with Inhibitor Peptides Containing Ester Bonds at Alternate Positions. <i>Biochemistry</i> , 2003, 42, 475-485.	2.5	108
26	Structure of Spin-Labeled Methylmethanethiolsulfonate in Solution and Bound to TEM-1 β -Lactamase Determined by Electron Nuclear Double Resonance Spectroscopy. <i>Biochemistry</i> , 2002, 41, 797-808.	2.5	7
27	Gas-Phase Photochemistry of the Photoactive Yellow Protein Chromophore trans-p-Coumaric Acid. <i>Journal of the American Chemical Society</i> , 2002, 124, 6194-6201.	13.7	71
28	Supramolecular Structure in Full-Length Alzheimer's β -Amyloid Fibrils: Evidence for a Parallel β -Sheet Organization from Solid-State Nuclear Magnetic Resonance. <i>Biophysical Journal</i> , 2002, 83, 1205-1216.	0.5	309
29	Inhibition of β -Amyloid(40) Fibrillogenesis and Disassembly of β -Amyloid(40) Fibrils by Short β -Amyloid Congeners Containing N-Methyl Amino Acids at Alternate Residues. <i>Biochemistry</i> , 2001, 40, 8237-8245.	2.5	257
30	pH dependent self assembly of β -amyloid(10-35) and β -amyloid(10-35)-PEG3000. <i>Journal of Applied Crystallography</i> , 2000, 33, 535-539.	4.5	43
31	Familial British Dementia: Expression and Metabolism of BRI. <i>Annals of the New York Academy of Sciences</i> , 2000, 920, 93-99.	3.8	18
32	Furin mediates enhanced production of fibrillogenic ABri peptides in familial British dementia. <i>Nature Neuroscience</i> , 1999, 2, 984-988.	14.8	146